|Mr. Mark Christopher Capone||Pres, CEO & Director||1.54M||N/A||1962|
|Mr. R. Bryan Riggsbee||CFO & Treasurer||590.53k||N/A||1971|
|Dr. Jerry S. Lanchbury Ph.D.||Chief Scientific Officer||706.94k||2.95M||1959|
|Mr. Richard M. Marsh Esq.||Exec. VP, Gen. Counsel & Sec.||708.87k||1.48M||1958|
|Mr. Alexander Ford||Pres of Myriad Genetic Laboratories, Inc.||N/A||N/A||1967|
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics, Inc.’s ISS Governance QualityScore as of July 1, 2018 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 6.